Sino Biopharmaceutical Reaches Major Out-Licensing Deal for TQC3721 with AstraZeneca

Overview

This report is Nomura's quick take on the exclusive licensing agreement signed between Sino Biopharmaceutical (01177.HK) and AstraZeneca for TQC3721. The deal centers on AstraZeneca obtaining the rights to develop, manufacture, and commercialize TQC3721 outside Greater China, as well as a global exclusive license for certain development programs. Nomura believes the event is positive for both the company and China's pharmaceutical sector.

Core views

Nomura's core views are: first, the USD200mn upfront payment, up to USD1.9bn in potential milestone payments, and sales royalties constitute a sizable transaction; second, the deal validates the company's capabilities in innovative drug R&D for respiratory diseases; third, this is the company's second out-licensing deal with a multinational pharmaceutical company in 2026, indicating that the company is catching up with the BD pace of leading large Chinese pharmaceutical companies; fourth, the deal helps alleviate investor concerns about a slowdown in the out-licensing trend for innovative Chinese drug molecules and supports the sector's rebound momentum.

Analysis framework

The report adopts an event-driven company research approach, assessing the licensing scope, transaction value, clinical stage, potential industry signals, and valuation maintenance, while evaluating the investment rating under a DCF target-price framework.

Methodology notes

• Valuation MethodDCF Model

  Discounted Cash Flow Valuation

  Nomura states that its HKD8.67 target price is based on a DCF model, assuming a WACC of 9.5% and a perpetual growth rate of 3%.

• Rating SystemNomura Equity Rating System

  Relative Benchmark Performance Rating

  Buy indicates that the analyst expects the stock to outperform the relevant benchmark over the next 12 months; this report maintains the Buy rating.

• Event AnalysisOut-Licensing Deal Assessment

  Commercialization and BD Validation of Innovative Drug Assets

  The report assesses the deal's impact on the company's R&D capabilities and sector sentiment based on the licensee, territorial rights, upfront payment, milestone payments, sales royalties, and clinical progress.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sino Biopharmaceutical 01177.HK

  Core covered asset and beneficiary of the transaction

  Strengths

  Receives a substantial upfront payment and potential milestone payments; its R&D and BD capabilities are validated by a multinational pharmaceutical company; Buy rating and target price maintained.

  Weaknesses

  The company still needs to demonstrate its ability to complete additional out-licensing deals and deliver product sales.

  Comparison

  Nomura believes the company is catching up with the transaction pace of other leading large Chinese pharmaceutical companies.

  Risks

  Sales weaker than expected; failure to advance additional out-licensing deals.

• AstraZeneca

  TQC3721 licensing partner

  Strengths

  Obtained the rights to develop, manufacture, and commercialize TQC3721 outside Greater China, as well as a global exclusive license for certain development programs.

  Weaknesses

  The report does not provide rating coverage for AstraZeneca.

  Comparison

  As the multinational pharmaceutical partner, its participation enhances the deal's validation significance.

  Risks

  The subsequent development and commercialization of TQC3721 remain subject to clinical and market uncertainties.

Key data

• Transaction AssetTQC3721The company's proprietary inhaled PDE3/4 dual inhibitor.
• PartnerAstraZenecaAstraZeneca obtained exclusive rights to develop, manufacture, and commercialize the product outside Greater China, as well as a global exclusive license for certain development programs.
• Upfront PaymentUSD200mnThe announcement disclosed that Sino Biopharmaceutical will receive an upfront payment.
• Potential Milestone PaymentsUp to USD1.9bnThere are also tiered royalties of up to the high teens.
• Clinical ProgressPhase III COPD nebulized suspension; Phase II COPD DPIPhase IIb results indicated best-in-class potential and were presented at ERS2025 Amsterdam.
• Rating and Target PriceBuy; HKD8.67Nomura maintains its rating and target price.
• Closing PriceHKD4.82 (2026-07-07)The closing price disclosed in the report.

Impact & implications

At the company level, the deal helps confirm the value of the TQC3721 asset, strengthens expectations for cash and potential milestone income, and reinforces perceptions of the company's R&D capabilities. At the sector level, the deal may improve market confidence in the out-licensing trend for innovative Chinese drugs and support a rebound in China's pharmaceutical sector.

Risks

• Sales weaker than expected.
• Failure to complete additional out-licensing deals.
• Subsequent clinical, regulatory, and commercialization progress for TQC3721 falls short of expectations.
• Sentiment toward the out-licensing trend for innovative Chinese drugs may weaken again.

What to watch

• The update call to be held by the company at 2:00 p.m. (HKT) on 2026-07-08.
• Subsequent data from the Phase III and Phase II clinical studies of TQC3721 for COPD in China.
• The pace at which AstraZeneca advances the overseas development program for TQC3721.
• Whether the company continues to complete out-licensing deals with multinational pharmaceutical companies in the remainder of 2026.
• Changes in the number and value of BD transactions and market sentiment in China's innovative drug sector.